Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

25.68 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.